0000950170-24-070991.txt : 20240607
0000950170-24-070991.hdr.sgml : 20240607
20240607191817
ACCESSION NUMBER: 0000950170-24-070991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240607
DATE AS OF CHANGE: 20240607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAKIANATHAN DEEPIKA
CENTRAL INDEX KEY: 0001270734
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 241031155
MAIL ADDRESS:
STREET 1: 160 BOVET ROAD, SUITE 408
STREET 2: C/O DELPHI VENTURES
CITY: SAN MATEO
STATE: CA
ZIP: 94402
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
ownership.xml
4
X0508
4
2024-06-05
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001270734
PAKIANATHAN DEEPIKA
C/O DELPHI VENTURES,
63 BOVET ROAD, SUITE 351
SAN MATEO
CA
94402
true
false
false
false
false
Common Stock
2024-06-05
4
S
false
463518
0.9582
D
346615
I
See footnote
Common Stock
2024-06-05
4
S
false
4526
0.9582
D
3385
I
See footnote
Common Stock
2024-06-06
4
S
false
117307
0.9828
D
229308
I
See footnote
Common Stock
2024-06-06
4
S
false
1145
0.9828
D
2240
I
See footnote
Common Stock
2024-06-07
4
S
false
229308
0.9507
D
0
I
See footnote
Common Stock
2024-06-07
4
S
false
2240
0.9507
D
0
I
See footnote
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
/s/ Matthew T. Potter, Attorney-in-Fact for Deepika Pakianathan
2024-06-07